Cargando…

Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk

BACKGROUND: Estrogens are crucial tumorigenic hormones, which impact the cell growth and proliferation during breast cancer development. Estrogens are metabolized by a series of enzymes including COMT, which converts catechol estrogens into biologically non-hazardous methoxyestrogens. Several studie...

Descripción completa

Detalles Bibliográficos
Autores principales: Onay, Ummiye V, Aaltonen, Kirsimari, Briollais, Laurent, Knight, Julia A, Pabalan, Noel, Kilpivaara, Outi, Andrulis, Irene L, Blomqvist, Carl, Nevanlinna, Heli, Ozcelik, Hilmi
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2254632/
https://www.ncbi.nlm.nih.gov/pubmed/18194538
http://dx.doi.org/10.1186/1471-2407-8-6
_version_ 1782151210031120384
author Onay, Ummiye V
Aaltonen, Kirsimari
Briollais, Laurent
Knight, Julia A
Pabalan, Noel
Kilpivaara, Outi
Andrulis, Irene L
Blomqvist, Carl
Nevanlinna, Heli
Ozcelik, Hilmi
author_facet Onay, Ummiye V
Aaltonen, Kirsimari
Briollais, Laurent
Knight, Julia A
Pabalan, Noel
Kilpivaara, Outi
Andrulis, Irene L
Blomqvist, Carl
Nevanlinna, Heli
Ozcelik, Hilmi
author_sort Onay, Ummiye V
collection PubMed
description BACKGROUND: Estrogens are crucial tumorigenic hormones, which impact the cell growth and proliferation during breast cancer development. Estrogens are metabolized by a series of enzymes including COMT, which converts catechol estrogens into biologically non-hazardous methoxyestrogens. Several studies have also shown the relationship between estrogen and cell cycle progression through activation of CCND1 transcription. METHODS: In this study, we have investigated the independent and the combined effects of commonly occurring CCND1 (Pro241Pro, A870G) and COMT (Met108/158Val) polymorphisms to breast cancer risk in two independent Caucasian populations from Ontario (1228 breast cancer cases and 719 population controls) and Finland (728 breast cancer cases and 687 population controls). Both COMT and CCND1 polymorphisms have been previously shown to impact on the enzymatic activity of the coded proteins. RESULTS: Here, we have shown that the high enzymatic activity genotype of CCND1(High )(AA) was associated with increased breast cancer risk in both the Ontario [OR: 1.3, 95%CI (1.0–1.69)] and the Finland sample [OR: 1.4, 95%CI (1.01–1.84)]. The heterozygous COMT(Medium )(MetVal) and the high enzymatic activity of COMT(High )(ValVal) genotype was also associated with breast cancer risk in Ontario cases, [OR: 1.3, 95%CI (1.07–1.68)] and [OR: 1.4, 95%CI (1.07–1.81)], respectively. However, there was neither a statistically significant association nor increased trend of breast cancer risk with COMT(High )(ValVal) genotypes in the Finland cases [OR: 1.0, 95%CI (0.73–1.39)]. In the combined analysis, the higher activity alleles of the COMT and CCND1 is associated with increased breast cancer risk in both Ontario [OR: 2.22, 95%CI (1.49–3.28)] and Finland [OR: 1.73, 95%CI (1.08–2.78)] populations studied. The trend test was statistically significant in both the Ontario and Finland populations across the genotypes associated with increasing enzymatic activity. CONCLUSION: Using two independent Caucasian populations, we have shown a stronger combined effect of the two commonly occurring CCND1 and COMT genotypes in the context of breast cancer predisposition.
format Text
id pubmed-2254632
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22546322008-02-27 Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk Onay, Ummiye V Aaltonen, Kirsimari Briollais, Laurent Knight, Julia A Pabalan, Noel Kilpivaara, Outi Andrulis, Irene L Blomqvist, Carl Nevanlinna, Heli Ozcelik, Hilmi BMC Cancer Research Article BACKGROUND: Estrogens are crucial tumorigenic hormones, which impact the cell growth and proliferation during breast cancer development. Estrogens are metabolized by a series of enzymes including COMT, which converts catechol estrogens into biologically non-hazardous methoxyestrogens. Several studies have also shown the relationship between estrogen and cell cycle progression through activation of CCND1 transcription. METHODS: In this study, we have investigated the independent and the combined effects of commonly occurring CCND1 (Pro241Pro, A870G) and COMT (Met108/158Val) polymorphisms to breast cancer risk in two independent Caucasian populations from Ontario (1228 breast cancer cases and 719 population controls) and Finland (728 breast cancer cases and 687 population controls). Both COMT and CCND1 polymorphisms have been previously shown to impact on the enzymatic activity of the coded proteins. RESULTS: Here, we have shown that the high enzymatic activity genotype of CCND1(High )(AA) was associated with increased breast cancer risk in both the Ontario [OR: 1.3, 95%CI (1.0–1.69)] and the Finland sample [OR: 1.4, 95%CI (1.01–1.84)]. The heterozygous COMT(Medium )(MetVal) and the high enzymatic activity of COMT(High )(ValVal) genotype was also associated with breast cancer risk in Ontario cases, [OR: 1.3, 95%CI (1.07–1.68)] and [OR: 1.4, 95%CI (1.07–1.81)], respectively. However, there was neither a statistically significant association nor increased trend of breast cancer risk with COMT(High )(ValVal) genotypes in the Finland cases [OR: 1.0, 95%CI (0.73–1.39)]. In the combined analysis, the higher activity alleles of the COMT and CCND1 is associated with increased breast cancer risk in both Ontario [OR: 2.22, 95%CI (1.49–3.28)] and Finland [OR: 1.73, 95%CI (1.08–2.78)] populations studied. The trend test was statistically significant in both the Ontario and Finland populations across the genotypes associated with increasing enzymatic activity. CONCLUSION: Using two independent Caucasian populations, we have shown a stronger combined effect of the two commonly occurring CCND1 and COMT genotypes in the context of breast cancer predisposition. BioMed Central 2008-01-14 /pmc/articles/PMC2254632/ /pubmed/18194538 http://dx.doi.org/10.1186/1471-2407-8-6 Text en Copyright © 2008 Onay et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Onay, Ummiye V
Aaltonen, Kirsimari
Briollais, Laurent
Knight, Julia A
Pabalan, Noel
Kilpivaara, Outi
Andrulis, Irene L
Blomqvist, Carl
Nevanlinna, Heli
Ozcelik, Hilmi
Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk
title Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk
title_full Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk
title_fullStr Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk
title_full_unstemmed Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk
title_short Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk
title_sort combined effect of ccnd1 and comt polymorphisms and increased breast cancer risk
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2254632/
https://www.ncbi.nlm.nih.gov/pubmed/18194538
http://dx.doi.org/10.1186/1471-2407-8-6
work_keys_str_mv AT onayummiyev combinedeffectofccnd1andcomtpolymorphismsandincreasedbreastcancerrisk
AT aaltonenkirsimari combinedeffectofccnd1andcomtpolymorphismsandincreasedbreastcancerrisk
AT briollaislaurent combinedeffectofccnd1andcomtpolymorphismsandincreasedbreastcancerrisk
AT knightjuliaa combinedeffectofccnd1andcomtpolymorphismsandincreasedbreastcancerrisk
AT pabalannoel combinedeffectofccnd1andcomtpolymorphismsandincreasedbreastcancerrisk
AT kilpivaaraouti combinedeffectofccnd1andcomtpolymorphismsandincreasedbreastcancerrisk
AT andrulisirenel combinedeffectofccnd1andcomtpolymorphismsandincreasedbreastcancerrisk
AT blomqvistcarl combinedeffectofccnd1andcomtpolymorphismsandincreasedbreastcancerrisk
AT nevanlinnaheli combinedeffectofccnd1andcomtpolymorphismsandincreasedbreastcancerrisk
AT ozcelikhilmi combinedeffectofccnd1andcomtpolymorphismsandincreasedbreastcancerrisk